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Abstract
Rationale—Collaterals lessen tissue injury in occlusive disease. However, aging causes 
progressive decline in their number and smaller diameters in those that remain (collateral 
rarefaction), beginning at 16 months-age in mice (ie, middle age), and worse ischemic injury—
effects that are accelerated in even 3 months-old eNOS−/− mice. These findings have found 
indirect support in recent human studies.
Objective—We sought to determine if other cardiovascular risk factors (CVRFs) associated with 
endothelial dysfunction cause collateral rarefaction, investigate possible mechanisms, and test 
strategies for prevention.
Methods and Results—Mice with nine different models of CVRFs of 4–12 months-age were 
assessed for number and diameter of native collaterals in skeletal muscle and brain, and for 
collateral-dependent perfusion and ischemic injury after arterial occlusion. Hypertension caused 
collateral rarefaction whose severity increased with duration and level of hypertension, 
accompanied by greater hindlimb ischemia and cerebral infarct volume. Chronic treatment of 
wildtype mice with L-NG-nitro-arginine methylester caused similar rarefaction and worse 
ischemic injury that were not prevented by lowering arterial pressure with hydralazine. Metabolic 
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syndrome, hypercholesterolemia, diabetes mellitus, and obesity also caused collateral rarefaction. 
Neither chronic statin treatment nor exercise training lessened hypertension-induced rarefaction.
Conclusion—Chronic CVRF presence caused collateral rarefaction and worse ischemic injury, 
even at relatively young ages. Rarefaction was associated with increased proliferation rate of 
collateral endothelial cells, effects that may promote accelerated endothelial cell senescence.
Keywords
collateral circulation; cardiovascular risk factors; endothelial dysfunction; hypertension; diabetes 
mellitus; metabolic syndrome; hyperlipidemia; obesity; cerebral circulation; ischemic stroke; 
peripheral vascular disease
Occlusive arterial disease is the most common cause of death in developed countries. The 
health care cost for cardiovascular disease and stroke, recently estimated at $312 billion, is 
more than any other diagnostic group.1 The presence of cardiovascular risk factors (CVRFs) 
increases the incidence of acute coronary syndrome, stroke, peripheral artery disease, and 
other occlusive vascular diseases. In data collected from 2007 to 2010, 35 percent of US 
adults were classified as obese, 33 percent had hypertension, and 38 percent met criteria for 
pre-diabetes1. In addition to increasing the risk of ischemic vascular disease, CVRF 
presence also predicts poorer outcomes in acute myocardial infarction,2 stroke,3 and 
peripheral artery disease.4 Current treatment for ischemic disease is limited to risk factor 
reduction to slow disease progression and revascularization strategies that include 
percutaneous intervention and open surgical bypass. Despite these efforts, a large fraction of 
patients are not adequately revascularized by traditional therapies; for example, only one 
third with coronary artery disease (CAD) achieves adequate revascularization.5 Furthermore, 
success with therapies to promote new blood vessel growth has thus far been limited.6
Most tissues in healthy individuals have a native (pre-existing) collateral circulation that 
provides protection against ischemic injury. Collaterals are arteriole anastomoses that cross-
connect a small fraction of the outer branches of adjacent arterial trees. They thus provide an 
alternative source of perfusion, whose magnitude depends on their number and diameter 
(collateral extent), in the event of arterial occlusion of one of the trees.7–9 If the obstruction 
is sustained or slowly developing, the collaterals enlarge their anatomic lumen diameter over 
days-to-weeks, which increases the collateral-dependent blood flow. A number of studies 
have found that aging, hypertension, diabetes and other CVRFs impair this collateral 
remodeling process.8,12–14 However, little is known about whether CVFRs affect the extent 
of the native collateral circulation before obstruction ensues.
Collateral extent measured in animals7 and estimates of collateral-dependent blood flow in 
humans15–17 indicate that wide variability exists in the abundance of these vessels among 
healthy individuals prior to occlusive disease. Studies in mice have found that differences in 
genetic background are a major contributor to this variation.7 Environmental factors also 
affect collateral extent; loss of collateral number and/or diameter (collateral rarefaction) 
occurs in brain and hindlimb of 16 months-old mice (~50 years in human), compared to 3 
months-old young adults.8 Moreover, rarefaction worsens with further aging, resulting in 
more severe injury in both tissues following arterial occlusion. This age-associated collateral 
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rarefaction, which was not seen in similarly sized end-arterioles in the surrounding trees, 
was associated with reduced eNOS activity and other markers of endothelial dysfunction in 
cells of the collateral wall.8 In support of a role for nitric oxide (NO) deficiency, collateral 
rarefaction in brain and hindlimb was greatly accelerated in eNOS−/− mice, occurring at 
even 3 months-age, becoming worse by 6 months, and resulting in more severe ischemic 
tissue injury.9 These results led us to suggest that eNOS-derived NO, through its anti-
proliferative, -inflammatory and –oxidative stress properties, serves as a “maintenance 
factor” for preserving collateral extent during aging.8
Reduced eNOS activity and NO bioavailability are central features of endothelial 
dysfunction that accompanies the presence of CVRFs. However, aside from the above-
mentioned studies of aging and targeted eNOS deficiency8,9 and studies of diabetic 
rodents,12,13 none has examined whether the presence of other CVRFs also cause collateral 
rarefaction. The major aim of the present study was to examine this possibility. We studied 
nine mouse models of hypertension, diabetes mellitus, obesity, hyperlipidemia, metabolic 
syndrome, combinations of these risk factors, and chronic exposure to cigarette smoke. In 
addition, since both chronic exercise training and statin treatment lessen endothelial 
dysfunction and risk factors in several or more of the above disturbances,18–21 we also 
examined whether these therapies could inhibit collateral rarefaction in one of the most 
common disease/risk factor —hypertension.
Materials and Methods
Details are available in the Online supplement.
Models of chronic cardiovascular risk factor presence
Unless indicated otherwise, each group had approximately equal male and female C57BL/6 
mice aged to ~eight months before studying, some while receiving certain treatments, to 
provide the following models of chronic CVRF presence. Hypertension: RTGMK renin 
transgenic mice (RTG+/−, RTG+/+) were generously provided by Dr Kathleen Caron; 
littermate controls (wildtype, wt) were used. Endothelial dysfunction: daily L-NG-nitro-
arginine methylester (L-NAME) from 1.5 to 8 months-old ± hydralazine, the latter to control 
for L-NAME-induced hypertension. Obesity: Lepob/ob. Hyperlipidemia and mild obesity: 
Ldlr−/− fed a high-fat western diet starting at 1.5 months-age. Mild hyperlipemia: Apoe−/− 
fed normal chow. Mild hypertension and mild hyperlipidemia: PpargL/+;Apoe−/− fed 
normal chow. Metabolic syndrome/Type 2 diabetes: Lepob/ob;Ldlr−/− (2KO, “double knock 
out”) studied at 6 months-age. Type 1 diabetes: Ins2Akita (Akita, male). Additional ages 
besides the above were examined for duration of cardiovascular risk factor exposure: 
Moderately hypertensive (RTG+/−) and hypertensive mice (RTG+/+): 1.5, 4, 8 and 12 
months-age; Ldlr−/− at 12 months-age; Akita at 10–11 months-age. Six week-old male mice 
were exposed to smoke from 6 cigarettes, 5 days per week, for 6 months. Control mice and 
those with risk factors, and/or their tissue sets, were coded and studied by blinded observer 
where possible.
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Hindlimb ischemia and cerebral stroke
After femoral artery ligation (FAL), perfusion and deficits ischemic appearance and leg use 
were measured.7–9 Infarct volume was determined 72 and 24 hours after permanent right 
middle cerebral artery (MCA) occlusion in the RTG and smoke-exposed mice, 
respectively.7,8
Angiography of cerebral and skeletal muscle collaterals, collateral remodeling
Angiography of pial and abdominal wall vasculature, after maximal dilation and fixation, 
was accomplished by infusion of Microfil with viscosity adjusted to fill the arterial and 
collateral circulations.7–9 For each mouse, all collaterals between the anterior cerebral artery 
(ACA) and MCA trees of both hemispheres were counted; their diameter at midpoint and 
tortuosity were obtained and an average value calculated for each mouse (similar methods 
were used in the abdominal wall). Remodeling of collaterals (anatomic increase in lumen 
diameter) in the right hemisphere was determined 72h and 24h after permanent MCA 
occlusion in the RTG and smoke-exposed mice, respectively.
Chronic daily statin treatment, chronic exercise training
Hypertensive RTG+/− mice and normotensive littermates received pitavastatin from 1.5 
through 8 months-age. In separate groups of RTG+/− and littermates, mice were swim-
trained from 2-to-8 months-age for 1h/day, 5 days/wk,22 or sham treated.
Proliferation of collateral wall cells, immunohistochemistry, immunoblotting
RTG+/− mice and age-matched wildtype littermates were infused with 5-ethynyl-2-
deoxyuridine (EdU) for 28 days by minipump, then processed for whole-mount 
immunohistochemistry. Immunoblot analysis was conducted on descending thoracic aorta. 
Fiber type composition of the tibialis anterior was determined using immunohistochemistry 
for myosin heavy chain isoforms.
Statistics
Data are mean ± SEM and were tested for significance (p<0.05) by t-tests or ANOVA 
followed by Bonferroni tests for comparison of more than two groups.
Results
Chronic hypertension results in more severe ischemia after acute femoral artery ligation
Mice were bred with different durations and severity of renin-dependent hypertension to 
determine if rarefaction of the native collateral circulation occurs. Mean arterial pressures of 
4, 8 and 12 months-old RTG+/− mice were 31, 22 and 31mmHg higher, respectively, than 
their normotensive age-matched littermates (Figure 1A, Online Table 1). Four months-old 
RTG+/+ were more hypertensive than heterozygotes (153±3 vs 136±3, P<0.001). Heart rate 
did not differ among the groups (Figure 1B). These findings agree with the original 
characterization of this model.21 Plantar and adductor perfusion dropped to lower values 
immediately after FAL in 8 months-old RTG+/− (“Post-op”, Figure 2A and 2B insets). 
Perfusion of the plantar region after ligation, as measured herein, correlates with collateral-
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dependent blood flow to the hindlimb determined with microspheres.24 Plantar perfusion 
was lower in the hypertensives over the first 7 days (Figure 2A, P<0.05). A similar trend 
was seen in the adductor region where lower perfusion, compared to the control group, 
reflects lower collateral-dependent perfusion.9,24 These findings suggest hypertensive mice 
have fewer and/or smaller-diameter native collaterals and may also experience a delay in 
collateral remodeling after FAL (both findings confirmed below). Baseline perfusion (“Pre-
op”) in plantar and adductor regions did not differ between the right and left hindlimb (data 
not shown) or between hypertensive and wildtype mice (left plantar: 1375 vs 1397, left 
adductor: 296 vs 336 perfusion units; P>0.9). We used distal FAL to produce moderate 
hindlimb ischemia thus minimal tissue damage. This consisted of cyanosis in one or more 
toes, with occasional nail loss in these B6 and B6;129SvEv strains that have abundant native 
collaterals.7,8 Hypertensive mice had worse scores for ischemic appearance and limb use 
one day after FAL (Figure 2C), a finding consistent with collateral rarefaction.
Progressive collateral rarefaction occurs with increasing duration and severity of 
hypertension and leads to more severe stroke
The above data suggest that renin-dependent hypertension causes lower collateral 
conductance, possibly due to collateral rarefaction. This is supported by the fact that higher 
arterial pressure in the hypertensive groups would be expected to increase rather than 
decrease collateral-dependent perfusion immediately after FAL if native collateral 
conductance was unaffected. However, the possibility of greater resistance above or below 
the collateral network in the RTG mice (eg, from increased angiotensin-dependent smooth 
muscle contraction) complicates this interpretation. Thus, to determine if hypertension 
causes rarefaction of native collaterals we measured their number and average diameter (at 
maximal dilation) in a different tissue. Because the complex three-dimensional orientation 
of the vascular trees in the hindlimb requires use of x-ray or CT angiography which have 
limited resolution and ability to distinguish collaterals from arteries and arterioles in terms 
of number and diameter,9 we developed an angiography method for use in skeletal muscle of 
the abdominal wall where the vascular trees are arranged in near-2-dimension. We first 
confirmed the reliability of the method in BALB/cByJ and B6 strains, which have wide 
differences in native collateral extent in multiple tissues (eg, brain, hindlimb and intestine)7 
(Online figure 1). We then used it in 8 months-old RTG+/− mice, finding reduced collateral 
number and diameter (Figure 3A, B). Similar results were obtained in brain (Figure 3), 
consistent with our previous studies showing that native collateral extent in one tissue 
reflects extent in other tissues of the same individual.7–9 Analysis at additional ages showed 
that loss of collateral number began between 4 and 8 months-age and was slightly greater by 
12 months-age (Figure 4A), whereas loss of diameter occurred earlier (16% decrease at 4 
months-age; Figure 4B). Thus, exposure to even 4 months of relatively moderate 
hypertension caused collateral rarefaction. Aging-induced loss of collateral diameter also 
preceded loss of collateral number.8
We next examined homozygous RTG mice to determine if more severe hypertension causes 
greater rarefaction. Compared to 4 months-old heterozygotes, 4 months-old RTG+/+ had 
greater reduction in collateral number and diameter (Figure 4B). To confirm that 
hypertension-induced rarefaction has a functional effect, we examined the severity of infarct 
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volume 72h after MCA occlusion. Eight months-old RTG+/− had a 1.8-fold increase in 
infarct volume (Figure 5A). Furthermore, collateral remodeling was reduced in the 
hypertensive mice by 34% when measured 72h after MCA occlusion (Figure 5B)—the time 
required for maximal remodeling of pial collaterals in B6 mice.7
Genetic-dependent differences in collateral extent in the brain are shared in the hindlimb of 
the same mouse.7,9 Therefore, to determine if the above pial collateral rarefaction of 4 
months-old RTG+/+ extends to hindlimb, we performed acute FAL as a functional test of 
collateral extent, since we found, above, that collateral extent in skeletal muscle of the 
abdominal wall correlated with flow immediately after hindlimb ligation in the above 8 
months-old mice. The reduction in perfusion immediately after FAL was greater in the 
RTG+/+ compared to RTG+/− mice (Figure 4C).
Chronic L-NAME causes collateral rarefaction independent of increased arterial pressure
A previous study found that collateral rarefaction occurred in brain and hindlimb of 3 
months-old B6 mice with genetic deletion of eNOS, while collaterogenesis in the embryo/
neonate was unaffected, leading to the suggestion that eNOS-derived NO is a “maintenance 
factor” for the native collateral circulation.9 However, whether rarefaction was caused by 
the mild hypertension also evident in eNOS−/− mice or from other consequences of eNOS 
deficiency was not evaluated. To answer this question and also determine if combined 
deficiency of eNOS, nNOS and iNOS causes greater collateral rarefaction (ie, if other NOS 
isoforms contribute to maintenance of native collaterals), B6 mice were treated with L-
NAME ± hydralazine (3.0 and 0.2 mg/ml, respectively, in drinking water) starting at 6 
weeks-age. Previous studies using these doses have shown that L-NAME causes a ~20 
mmHg increase in arterial pressure that is reduced by hydralazine25—findings that were 
confirmed herein (Online Table 1). At 8 months-age, plantar and adductor perfusion both 
fell to lower values immediately after FAL in the L-NAME group compared to control mice, 
and limb use and ischemic appearance were worse when measured the next day (Figure 2D–
F). Collateral number and diameter were reduced in brain and abdominal wall (Figure 3C, 
D). Recovery of plantar and adductor perfusion and hindlimb use were strongly impaired in 
L-NAME treated mice. The above changes are similar in magnitude to those reported for 3 
months-old eNOS−/− mice,9 suggesting that the presence or absence of nNOS and iNOS 
does not influence native collateral extent or remodeling. Co-administration of hydralazine 
reduced the hypertension but had no significant effect on the above measurements, except 
for lessening ischemic appearance score. These data strengthen previous evidence that 
eNOS-derived NO is required to maintain native collaterals in tissues and permit full 
collateral remodeling after arterial obstruction.9 They also do not support a role for nNOS 
and iNOS in these processes. In addition, they demonstrate that deficiency in eNOS causes 
collateral rarefaction in brain and skeletal muscle that is independent of the accompanying 
hypertension.
Increased cell proliferation and tortuosity in collaterals of hypertensive mice
How might deficient eNOS-NO/endothelial dysfunction cause collateral rarefaction? 
Collaterals form late in gestation and have no tortuosity at birth.32 However, this hallmark of 
collaterals in adult tissues rapidly develops over the next 3 weeks, followed by a slower 
Moore et al. Page 6













increase through 3 months-age that peaks at 16 months.8, 32 Beginning at 16 months, 
collaterals evidence a loss of diameter that is not seen in distal-most arterioles.8 This is 
accompanied by a progressive decline in tortuosity at 24 and 31 months. Since the distance 
between the crowns of adjacent arterial trees (ie, the width of the collateral zone) does not 
decrease between birth and advanced aging,8, 32 this biphasic pattern of change in collateral 
diameter and tortuosity prompted speculation8 that collateral endothelial cells have a higher 
proliferation rate than arterioles of similar diameter, hence their progressively increased 
tortuosity from birth through middle age (16 months). And furthermore, that this increase in 
proliferation favors proliferative senescence of collateral endothelial cells with additional 
aging, leading to loss of collaterals and a decline in diameter and tortuosity in those that are 
still present at advanced age.8
Given that RTG mice evidence rarefaction at a much younger age (Figures 3,4), we sought 
to determine if this is accompanied by increased tortuosity since this is suggested by the 
above findings to be a surrogate for endothelial proliferation. Compared to wildtype mice, 
collateral tortuosity increased 24% more in 4 months-old, 56% more in 8 months-old, and 
24% more in 12 months-old RTG+/− mice (Figure 6A). This biphasic pattern recapitulates, 
at a much earlier age, the pattern seen in mice with advanced age,8 suggesting that collateral 
rarefaction in RTG and aged mice may share common mechanisms and that elevated 
angiotensin and/or hypertension accelerates the process. To determine directly if the 
increase in tortuosity in hypertensive mice is accompanied by increased proliferation, EdU 
was infused by minipump for 28 days before sacrifice. Increased proliferation of cells in the 
collateral wall with location and nuclear orientation characteristic of endothelial cells was 
observed in 8 months-old RTG+/− mice, with a similar trend seen at 4 months (Figure 6B). 
These and the tortuosity findings suggest that collateral rarefaction, evident in relatively 
young mice with renin-dependent hypertension, may be caused by an increase in the 
already-accelerated proliferative senescence of collateral endothelial cells that accompanies 
natural aging. The small number of proliferating cells observed in non-vascular cells of the 
pia mater (Figure 7), which could include fibroblasts and/or immune cells of peripheral or 
central origin, did not differ between wild-type and hypertensive RTG+/− mice (0.24 ± 0.03 
vs 0.20 ± 0.05 cells/100 μm2, p = 0.47, n = 6 of each strain, randomly selected fields at or 
within the vicinity of the collateral zone). Hazama et al33 reported that young spontaneously 
hypertensive rats (which are more hypertensive than the mice studied herein, had, compared 
to normotensive controls, increased proliferating cells in the watershed zones [where 
collaterals reside] that they described as endothelial, smooth muscle and adventitial cells 
within the walls of pial and intracerebral arterioles, as well as glial and arachnoid cells in the 
surrounding pia. However, the authors did not make clear whether the pial arterioles were 
collaterals, nor was it evident which cell types had significantly increased proliferation.
Obesity, hyperlipidemia, diabetes mellitus and metabolic syndrome also cause collateral 
rarefaction
We examined other cardiovascular risk factors in addition to hypertension. All mouse 
models were on the B6 background and 8 months-age except metabolic syndrome (6-months 
age) (Online Table 1). Responses to FAL in obese mice (Lepob/ob) were equivalent to 
wildtype, as were native pial collateral number; however collateral diameter was reduced 
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(Figure 7A). Mice with hyperlipidemia and moderate obesity (Ldlr−/− fed a western diet) 
tended to have lower perfusion immediately after FAL (P=0.05), consistent with lower 
collateral extent, and lower recovery of perfusion thereafter (P=0.06), and fewer native pial 
collaterals (P=0.06) (Figure 7B). Mildly hyperlipidemic mice (Apoe−/− fed a normal diet) 
had lower perfusion immediately after FAL (Online figure 2). Mice with mild hypertension 
(~10 mmHg increase) and hyperlipidemia (PpargL/+;Apoe−/− fed a normal diet) had lower 
perfusion immediately after FAL and fewer pial collaterals (Online figure 2). Responses to 
FAL in mice with Type 1 diabetes (Ins2Akita) were consistent with rarefaction of native 
collaterals in hindlimb; however, only pial collateral number (not diameter) trended lower 
(P=0.07) (Figure 7C). Since diabetes is well-known to induce endothelial dysfunction and 
impaired flow-mediated dilation,34 the latter could also contribute to the hindlimb findings. 
Consistent with this, we found a near-complete loss of NO-dependent flow-mediated 
dilation of the feed arteries that supply the prominent collaterals in the gracilis muscles 
(Online figure 3). Mice with metabolic syndrome (Lepob/ob;Ldlr−/−) that have Type 2 
diabetes, hypertension, moderate obesity, and hyperlipidemia (Online Table 1) had 
pronounced reduction in perfusion following FAL both acutely and over 21-days, and 
reduced number and diameter of pial collaterals (Figure 7D). Although the trends toward 
fewer pial collaterals in 8 months-old Akita mice did not become significant at 11–12 
months-age, they did when both ages were combined and also almost did-so in the Ldlr−/− 
mice (Online figure 4). Measurements of hindlimb use and ischemic appearance support the 
above findings for these models of CVRF presence (Online figure 5).
Neither pitavastatin nor exercise training prevented collateral rarefaction in hypertension
The chronic presence of the above cardiovascular risk factors in humans and animal models, 
including the above, are known to associate with deficiencies in endothelial function and 
eNOS-NO29. Statins reduce endothelial dysfunction and increase eNOS-NO activity/
bioavailability, among other actions.35 Since the above and our previous data in aging and 
eNOS−/− mice implicate eNOS deficiency/endothelial dysfunction in rarefaction of 
collaterals,8,9 we asked whether chronic statin treatment from 1.5 through 8 months-age 
could prevent rarefaction in RTG+/− hypertensive mice. However, neither the deficits 
following FAL nor pial collateral rarefaction were affected by pitavastatin (Online figure 6). 
Chronic statin treatment did not reduce arterial pressure in the RTG+/− mice but did in the 
normotensive vehicle-treated controls (Online figure 7).
Exercise training is well known to lessen endothelial dysfunction and impaired eNOS-NO 
activity/bioavailability in hypertension and aging.36 We therefore examined whether chronic 
daily swimming from 2 through 8 months-age would prevent collateral rarefaction in 
RTG+/− mice. However, like pitavastatin treatment, exercise did not prevent the deficits in 
perfusion following FAL nor rarefaction of pial collaterals (Online figure 8). This was 
despite a training regimen sufficient to cause modest resting bradycardia, reduction in 
arterial pressure, and skeletal muscle fiber type switching (Online figures 9, 10).
Although rarefaction of native collaterals in brain and indices of it in hindlimb (flow 
immediately after FAL) were not lessened by chronic statin treatment or exercise training, 
hindlimb use and ischemic appearance were improved by both treatments (Online figure 11). 
Moore et al. Page 8













This was true for both wildtype and hypertensive mice. Consistent with this, recovery of 
hindlimb flow trended higher with pitavastatin treatment (however this was not the case with 
exercise training) (Online figures 5,7). This may result—in the case of exercise training—
from its effect to increase capillary density and improve oxygen utilization (eg, increased 
mitochondrial volume/fiber length),37 and—in the case of statin treatment—to increase 
Sirt-1 and eNOS/NO thus reduce inflammation and leukocyte/platelet adhesion.18 These 
effects favor increased capillary flow and capillary surface area receiving flow, which can 
both improve tissue oxygenation without a significant change in overall blood flow to a limb 
or organ.
No significant differences were observed in male and female mice in any of the above 
experiments (~equal numbers were studied, except for Type 1 diabetic mice that were all 
male).
Trend toward collateral rarefaction and increased infarct volume with exposure to 
cigarette smoke
Six months of exposure to cigarette smoke caused a trend toward loss of collaterals and 
increased infarct volume after middle cerebral artery occlusion (Online figure 12). Absence 
of a significant effect may reflect the need for a larger sample size and/or that humans 
generally smoke for a longer time than 6 months before encountering smoking-related health 
problems, although 6 months amounts to 17–20% of the C57BL/6 mouse lifetime of 30–36 
months.
Discussion
In the present study, hypertension caused rarefaction whose severity increased with the level 
and duration of hypertension over 4-to-12 months-age. This resulted in more severe stroke 
and hindlimb injury after acute arterial occlusion. Hypertensive rarefaction occurred more 
rapidly than with aging alone, ie, diameter and number had declined significantly by 4 and 8 
months-age in moderately hypertensive RTG+/− mice, respectively, whereas significant loss 
of diameter and number were not seen until 16 and 24 months-age, respectively, with aging 
alone.8 These latter ages in B6 mice are ~equivalent to 50 and 67 years of age in humans. 
This “premature” rarefaction that occurred with even moderate hypertension and duration (8 
months-old RTG+/− mice) was accompanied by—in the collaterals that had not been lost—a 
decrease in expression of markers of eNOS-derived NO activity/bioavailability, an increase 
in rate of endothelial cell proliferation, and a loss of diameter and tortuosity (length) which 
is a hallmark of collaterals.8, 32 Chronically increased proliferation rate, when accompanied 
by a decline in diameter and length, suggest the possibility of accelerated senescence thus 
progressive loss of collateral wall cells. These findings support a previously proposed 
hypothesis8,9 that endothelial dysfunction caused by natural aging, hypertension and other 
CVRFs results in reduced NO-mediated inhibition of proliferation, oxidative stress, 
inflammation, and thus increased aging of collateral endothelial cells leading to apoptosis 
and loss of length, diameter and ultimately number. Consistent with this hypothesis and our 
conclusion reached in a previous study of eNOS−/− mice that eNOS-NO is required to 
maintain collateral number and diameter during aging,9 chronic treatment with L-NAME 
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from 1.5-to-8 months-age caused collateral rarefaction and greater cerebral infarct volume 
and hindlimb ischemia. It is also noteworthy that the severity of rarefaction and hindlimb 
ischemia, as well as deficit in collateral remodeling and recovery of perfusion caused by L-
NAME treatment, were similar to that reported in eNOS−/− mice.9 This suggests that other 
NOS isoforms do not participate in maintaining native collaterals or in their remodeling in 
occlusive disease, nor do these isoforms compensate in these activities when eNOS is 
deficient.
Comparable levels of hypertension (20–22 mmHg increase) in 8 months-old RTG+/− and L-
NAME-treated mice were accompanied by similar levels of collateral rarefaction. L-NAME-
induced rarefaction was not reduced when hypertension was prevented by simultaneous 
administration of hydralazine (arterial pressure remained 7 mmHg above baseline; non-
significant). We thus postulate that reduced NO but not the mild hypertension in this model, 
causes collateral rarefaction. This is supported by our finding that well-characterized models 
of metabolic syndrome, hypercholesterolemia, diabetes mellitus, and to a lesser degree, 
obesity, ie, CVRFs that have in common reduced eNOS-NO but not hypertension, were also 
accompanied by collateral rarefaction. It is also noteworthy that inhibition of NO 
production, either genetically or by L-NAME, causes upregulation of the renin-angiotensin 
system (RAS).38, 39 This plus evidence that chronic increase in angiotensin causes 
endothelial dysfunction independent of angiotensin’s direct vasoconstrictor and hypertensive 
effects40 may explain the above results in the RTG and L-NAME±hydralazine experiments. 
However, since a greater level of hypertension and thus, potentially, collateral wall stress 
could itself cause rarefaction, it remains to be determined if a normal-renin model of 
hypertension also causes collateral rarefaction. In support of this, endothelial dysfunction 
accompanies essential hypertension in humans.41 And indirect evidence consistent with 
reduced collateral extent has been reported in the brain and heart of individuals with 
essential hypertension (discussed below).42, 43 Interestingly, reduced capillary density in 
skin and brain has been reported in human essential hypertension,44, 45 as well as in skeletal 
muscle,46 intestinal mesentery,47 skin of spontaneously hypertensive rats,48 and brain of 
renal hypertensive rats.49 Reduction in arteriole density was also observed in the rat studies, 
although collateral vessels were not assessed. Spontaneously hypertensive rats have larger 
infarctions following MCA occlusion and less collateral-dependent blood flow than their 
normotensive counterparts;50 however, dysregulated vascular tone and limited dilatory 
reserve were theorized as the responsible mechanism in these early studies. Interestingly, 
both pressure-dependent and independent effects of angiotensin have been linked to 
microvascular rarefaction51, 52 that is associated with increased endothelial cell apoptosis 
and oxidative stress.53
In 8 week-old eNOS−/− mice whose arterial pressure under pentobarbital anesthesia was not 
significantly elevated, capillary and arteriole densities in cardiac and skeletal muscles were 
not different.54 By 12 months-age, arteriolar densities were 15% lower, an effect prevented 
by hydralazine. These findings suggest that hypertension caused by eNOS deficiency results 
in arteriolar rarefaction. However, collateral vessels, which have many properties unique 
from arterioles,55 were not examined in the above study. The purpose of our study did not 
include studying the effect and mechanisms by which certain CVRFs reduce collateral 
remodeling after arterial ligation, because many reports have addressed this topic.12–14 We 
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used the hindlimb ischemia model to determine blood flow immediately after ligation, as a 
functional index of CVRF-induced rarefaction of the pre-existing collateral circulation in the 
hindlimb. Our purpose was to determine if the anatomic rarefaction that we measured 
directly in the brain and skeletal muscle of the abdominal wall might also occur in hindlimb. 
These flow values immediately after ligation, which are important to the purpose of the 
paper, are shown in the bar graphs of Figure 1A, B, D, E and Figure 7A–D, as well as 
several of the online figures. We measured hindlimb flow over 21 days because recovery of 
flow is determined by both collateral extent before ligation and collateral remodeling 
thereafter. The data in these figures thus add functional significance to our findings of 
CVRF-induced collateral rarefaction in brain and abdominal wall. Parenthetically, the time-
course data also provide confirmation of impaired recovery of flow in the presence of 
certain CVRFs reported by others, and provide additional data about recovery in CVRF 
models not reported elsewhere. It was previously shown56 in eNOS−/− mice that hindlimb 
flow after FAL was only decreased until day-7, suggesting delayed collateral growth after 
FAL. However, histology found no differences in collateral diameter in eNOS−/−, wildtype 
and eNOS-transgenic mice at 1 and 3 weeks. Administration of an NO donor induced 
vasodilation in eNOS−/− but not wildtype mice, suggesting impaired dilation of collaterals 
and/or the vascular beds upstream or downstream of the collateral network, since collateral 
vasoactivity was not directly measured. This study demonstrated that eNOS activity is 
crucial for NO-mediated vasodilation of peripheral vessels in the setting of arterial 
occlusion.
Recent studies in humans without obstructive disease, ie, wherein the confounding effects of 
differences in collateral remodeling on estimates of native collateral extent are avoided, have 
reported findings consistent with our results. In individuals lacking identifiable CAD, the 
presence of hypertension associated with (p<0.006) low collateral flow index (CFI) on 
multivariate analysis, while no significant association was found for other classic CVRFs 
including diabetes and obesity (p=0.07 for age).42 Since collateral extent can only be 
determined postmortem in humans, CFI remains the best indicator, albeit indirect, of 
conductance of the collateral network and thus collateral extent. Likewise, a similar index—
collateral score measured as the extent of retrograde filling of the occluded tree on 
neuroimaging of patients with acute ischemic stroke—was associated when low with age, 
hypertension, metabolic syndrome, and higher plasma glucose, D-dimer and uric acid, but 
not with other classic CVRFs.43 On multivariate analysis, only age, metabolic syndrome and 
hyperuricemia remained independent predictors of poor pial collateral score. While studies 
in mice benefit from the ability to hold genetic and environmental factors constant, larger 
patient samples will be required to address whether congruence exists between humans and 
our findings in mice.
Statin therapy is associated with improvements in endothelial function, and newer agents 
such as pitavastatin have shown promise in promoting eNOS activity/signaling,18, 57 anti-
senescence factors,18, 58 and improved collateral-dependent perfusion in CAD59 and acute 
ischemic stroke.60 Because our current and previous results8,9 implicate decreased eNOS 
activity/vascular senescence in CVRF-associated collateral rarefaction, we tested 
pitavastatin administration in hypertensive mice from 1.5-to-8 months-age. However, no 
inhibition of rarefaction was observed in brain or hindlimb. Likewise, no inhibition was seen 
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with chronic exercise training over the same duration. This was despite changes indicative 
of training-induced cardiovascular conditioning in hypertensive and normotensive mice 
(resting bradycardia and muscle fiber-type switching) that have been reported in similar 
swim-training programs.61 These negative results were unexpected, since exercise training 
increases eNOS activity in arteries and arterioles20, 62 and decreased senescence of vascular 
wall cells.21 In addition, 2.5 months of swim-training reduced arterial pressure and heart 
rate, caused fiber-type switching, restored eNOS activity and prevented capillary rarefaction 
in spontaneously hypertensive rats.61 Since the training effects we observed were small, it 
remains possible that a more vigorous training program, or its testing in the presence of 
renin-independent hypertension or a different CVRF, would find that exercise training 
lessens or prevents collateral rarefaction.
We were also surprised that recovery of flow after FAL, which is dependent on both native 
collateral extent prior to obstruction and subsequent remodeling of collateral diameter, failed 
to improve in normotensive and hypertensive groups following exercise-training, since 
better recovery has been reported in several studies. Yang et al. found in rats that femoral 
artery ligation, followed by 4 weeks of treadmill training, increased collateral-dependent 
flow more than with bFGF alone.63 They also found that L-NAME abolished the 
improvement in recovery with exercise. However, microvascular density was not affected, 
suggesting that increasing NO with exercise training may predominantly occur in larger 
vessels thus improve eNOS-dependent dilation.64 Interestingly, collateral-dependent 
perfusion is partly dependent on flow-mediated dilation upstream of the collateral network.9 
Furthermore, increased NO-dependent collateral conductance following acute arterial 
obstruction was seen whether the exercise regimen was begun before or after the occlusive 
event.65 It is important to note, however, that previous studies have not quantified native 
collateral extent in exercised animals in the presence or absence of CVRFs. Endurance 
training augmented coronary CFI in a healthy individual66 and in normal coronary artery 
trees of patients with CAD elsewhere in the heart.67 However, the short 3–6 month duration 
of training suggests these findings may result from improved outward remodeling of 
existing collaterals rather than inhibition of age- or CVRF-induced rarefaction. Prior 
exercise training is associated with improved outcome and reduced infarct size in the setting 
of stroke.68 While the coronary effects might reflect improved remodeling in collaterals 
already recruited by CAD, whether the latter results in stroke reflect improved remodeling, 
less rarefaction, better autoregulation of blood flow within trees adjacent to the occluded 
territory or enhanced neuroprotective mechanisms were not addressed. Our findings suggest 
that the beneficial effects of exercise in the above studies may reflect greater outward 
remodeling of collaterals and angiogenesis in the downstream tissues, rather than from 
preservation of native collaterals, although metabolic changes could also contribute. A 
stronger exercise regime remains to be tested for inhibition of collateral rarefaction.
While the focus in the present study was on rarefaction of the native collateral circulation, 
we also examined recovery of perfusion after femoral artery ligation, which is dependent on 
both native extent and collateral remodeling. Diabetes, hypertension, metabolic syndrome 
and L-NAME reduced recovery, whereas obesity and hyperlipidemia did not. Although we 
only measured remodeling in the hypertensive model (where it was reduced, Figure 5B), 
impaired recovery after arterial obstruction has been well-documented in animal models of 
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diabetes mellitus,69 hypertension,70 obesity,71 metabolic syndrome,72 and hyperlipidemia.73 
Similarly, human studies have also reported reduced collateral score/status in patients with 
diabetes mellitus,42, 43, 66 hypertension,43, 74, 75 and obesity/metabolic syndrome/
hyperlipidemia.43, 76 As with the exercise studies discussed above, whether these 
observations reflect rarefaction of native collaterals, impaired remodeling or other 
mechanisms is not known. However, our finding of reduced remodeling in hypertensive 
mice is in agreement with two recent studies.77, 78
Hyperlipidemic and obese mice did not show any significant deficit in recovery of 
perfusion. In contrast, van Weel et al. found that hyperlipidemic mice with the Apo3*Leiden 
mutation and altered diet showed strong impairment in recovery after FAL, accompanied by 
reduced collateral remodeling.79 This disagreement might be explained by a predominance 
of low-density lipoprotein in Ldlr−/− versus greater very low-density lipoprotein in the 
Apo3*Leiden mice. Interestingly, mice with metabolic syndrome, which was produced by a 
combined deletion of Ldlr and Leptin (ie, 2KO) showed collateral rarefaction and strong 
impairment in recovery from hindlimb ischemia. In addition to obesity and hyperlipidemia, 
the 2KO mouse is characterized by high fasting blood glucose and insulin resistance.80 Yan 
et al. recently reported that Type 2 diabetic/insulin resistant mice have more pronounced 
impairment in recovery from hindlimb ischemia than Type 1 diabetic mice.81 They also 
found smaller baseline collateral diameters in the hindlimb, similar to our finding among 
pial collaterals in 2KO mice.
Findings in our 2KO genetic model of metabolic syndrome might be viewed at variance 
with two previous studies. Pial collateral number was increased in 10 week-old GK rats that 
develop a type of lean Type 2 diabetes,10 while in the present study pial collateral number 
(and diameter and collateral-dependent flow immediately after ligation in the hindlimb) 
were decreased in the 2KO mice. This contrast might arise from the different 
pathophysiology of the two disease models plus unknown genetic variants present in the GK 
rat. Likewise, in 4–5 month-old Leprdb/db mice (leptin receptor deficient mice on the same 
background as the Leptinob/ob leptin-deficient mice studied herein) that were studied as a 
model of Type 2 diabetes, no differences were found in pial collateral number.11 However, 
these data are similar to our findings in 8 months-old Leptinob/ob obese mice that, however, 
have almost twice the body weight and half the blood glucose as in the former study. It is 
likely that differences in age and phenotype/pathophysiology contribute to these 
discrepancies.
The above previous and current studies show that different CVRFs have variable effects on 
inhibiting recovery of perfusion, collateral remodeling, and collateral rarefaction. Those risk 
factors associated with the most severe rarefaction also have the most severe perfusion 
deficit and tissue injury following acute arterial obstruction. This is in agreement with our 
previous studies in mice, as well has studies by others in humans, showing the importance of 
variation in abundance of the native pial collateral circulation in determining outcome after 
acute ischemic stroke.
Why are collaterals so susceptible to rarefaction? A consideration of the unique 
hemodynamic environment in which collaterals reside offers a potential clue. In the absence 
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of obstruction, flow and thus shear stress in the central-most segment of collaterals that 
cross-connect the crowns of adjacent arterial trees is very low and disturbed, ie, it slowly 
oscillates in direction, resulting in little or no net flow—at least in the brain and skeletal 
muscle of the anesthetized mouse.32 Since the kinetic energies of the colliding flows are 
converted to potential energy, circumferential wall stress is increased. In addition, these low-
flow conditions favor oxygen content in the lumen of collaterals to be low and toward 
equilibration with tissue PO2 due to diffusion to surrounding tissue. It is well known that 
chronic low and disturbed shear stress, high wall stress, and low oxygen favor endothelial 
dysfunction, oxidative stress, inflammation, cell proliferation and thus athero- and 
arteriosclerosis in larger arteries (ie, an accelerated aging-like phenotype),82 whereas in the 
microcirculation, collateral-like intra-tree arteriole anastomoses that can appear transiently 
during development are predominantly pruned away in most but not all tissues, eg, intestinal 
mesentery.32,83 By contrast, in healthy adult tissue, collaterals persist even though they 
reside in this “at-risk environment.” However, we postulate that this makes them particularly 
vulnerable, much like “canaries in a mine shaft”, to further stresses to the vascular wall 
caused by chronic hypertension, hyperglycemia, dyslipidemia, and natural aging. Our 
finding of markers of endothelial dysfunction (decreased eNOS and phospho-VASP) in 
collaterals but not in the femoral artery or aorta of mildly hypertensive mice is consistent 
with this hypothesis. Moreover, under normal conditions endothelial cells are one of the 
least proliferative cell types, with turnover estimated at ≥ 43 days.84 As such, endothelial 
cells undergo replicative senescence under conditions of sustained proliferation, which then 
leads to premature apoptosis.85,86 As collateral endothelial cells reach there replicative 
maximum, preferential loss, or rarefaction, of collateral wall cells would be expected. In line 
with this prediction, pial collateral tortuosity increased significantly between 4 and 8 
months-age in the hypertensive mice, followed by progressive collateral rarefaction and 
gradual decrease in tortuosity thereafter. This recapitulates the sequence observed in our 
previous study on aged C57Bl/6 mice, in which tortuosity reached a maximum at 16 
months-age, followed by incremental collateral rarefaction and decreased tortuosity in the 
collaterals that remained present.8
In conclusion, the present study demonstrates that cardiovascular risk factors when present 
beginning at a young age cause—compared to aging alone8—“premature” rarefaction of the 
native collateral circulation, resulting in greater tissue injury in ischemia. Hypertension and 
metabolic syndrome caused the most severe rarefaction. If risk factor-induced rarefaction 
also occurs in humans as indirect findings suggest,42, 43, 66, 74–76 loss of these natural bypass 
vessels, combined with the elevated risk of atherosclerosis and increased propensity for 
thrombosis and peripheral vasoconstriction, create a “perfect storm” for poor overall 
prognosis. These considerations thus add additional weight to the already prodigious 
rationale for adopting lifestyles and treatments to mitigate modifiable CVRFs. Further 
elucidation of the mechanisms underlying collateral rarefaction, beyond endothelial 
dysfunction and proliferative changes as identified herein, will require additional 
investigation. However, identifying the mechanisms that endow collaterals with their 
hallmark increased proliferation and tortuosity may lead to insights into how collateral 
rarefaction might be lessened or prevented.
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Akita Ins2Akita mouse strain with spontaneous mutation of insulin receptor-2 
causing destruction of beta cells of pancreas thus diabetes mellitus
B6 C57BL/6J inbred mouse strain
CVRFs cardiovascular risk factors
EdU 5-ethinyl-2′-deoxyuridine
FAL femoral artery ligation
L-NAME L-NG-nitro-arginine methylester
MCA middle cerebral artery
NO nitric oxide
PCA posterior cerebral artery
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2KO Lepob/ob;Ldlr−/− “double knockout” (2KO) model of metabolic syndrome
References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford 
ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, 
Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli 
A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, 
Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Executive 
summary: Heart disease and stroke statistics--2013 update: A report from the american heart 
association. Circulation. 2013; 127:143–152. [PubMed: 23283859] 
2. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, 
Peterson ED, Roe MT. Risk adjustment for in-hospital mortality of contemporary patients with 
acute myocardial infarction: The acute coronary treatment and intervention outcomes network 
(action) registry-get with the guidelines (gwtg) acute myocardial infarction mortality model and risk 
score. Am Heart J. 2011; 161:113–122. [PubMed: 21167342] 
3. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, Kreitsch P, Mackert BM, 
Nabavi DG, Nolte CH, Pohls W, Schmehl I, Schmitz B, von Brevern M, Walter G, Heuschmann 
PU. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. 
Neurology. 2011; 77:965–972. [PubMed: 21865573] 
Moore et al. Page 15













4. Virkkunen J, Heikkinen M, Lepantalo M, Metsanoja R, Salenius JP. Diabetes as an independent risk 
factor for early postoperative complications in critical limb ischemia. J Vasc Surg. 2004; 40:761–
767. [PubMed: 15472606] 
5. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, 
Traverse JH, Henry TD. Patients with coronary artery disease not amenable to traditional 
revascularization: Prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010; 75:886–891. 
[PubMed: 20432394] 
6. Sun L, Bai Y, Du G. Endothelial dysfunction--an obstacle of therapeutic angiogenesis. Ageing Res 
Rev. 2009; 8:306–313. [PubMed: 19389489] 
7. Sealock R, Zhang H, Lucitti JL, Moore SM, Faber JE. Congenic fine-mapping identifies a major 
causal locus for variation in the native collateral circulation and ischemic injury in brain and lower 
extremity. Circ Res. 2014; 114:660–671. [PubMed: 24300334] 
8. Faber JE, Zhang H, Lassance-Soares RM, Prabhakar P, Najafi AH, Burnett MS, Epstein SE. Aging 
causes collateral rarefaction and increased severity of ischemic injury in multiple tissues. 
Arterioscler Thromb Vasc Biol. 2011; 31:1748–1756. [PubMed: 21617137] 
9. Dai X, Faber JE. Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and 
impairs activation of a cell cycle gene network during arteriogenesis. Circ Res. 2010; 106:1870–
1881. [PubMed: 20431061] 
10. Li W, Prakash R, Kelly-Cobbs AI, Ogbi S, Kozak A, El-Remessy AB, Schreihofer DA, Fagan SC, 
Ergul A. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal 
cerebral ischemia. Diabetes. 2010; 59:228–35. [PubMed: 19808897] 
11. Akamatsu Y, Nishijima Y, Lee CC, Yang SY, Shi L, An L, Wang RK, Tominaga T, Liu J. 
Impaired leptomeningeal collateral flow contributes to the poor outcome following experimental 
stroke in the type 2 diabetic mice. J Neurosci. 2015; 35:3851–64. [PubMed: 25740515] 
12. Silvestre JS, Smadja DM, Lévy BI. Postischemic revascularization: from cellular and molecular 
mechanisms to clinical applications. Physiol Rev. 2013; 93:1743–802. [PubMed: 24137021] 
13. de Groot D, Pasterkamp G, Hoefer IE. Cardiovascular risk factors and collateral artery formation. 
Eur J Clin Invest. 2009; 39:1036–47. [PubMed: 19845740] 
14. Teunissen PF, Horrevoets AJ, van Royen N. The coronary collateral circulation: genetic and 
environmental determinants in experimental models and humans. J Mol Cell Cardiol. 2012; 
52:897–904. [PubMed: 21959171] 
15. Shuaib A, Butcher K, Mohammad AA, Saqqur M, Liebeskind DS. Collateral blood vessels in acute 
ischaemic stroke: A potential therapeutic target. Lancet Neurol. 2011; 10:909–921. [PubMed: 
21939900] 
16. Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: Development and 
clinical importance. Eur Heart J. 2013; 34:2674–2682. [PubMed: 23739241] 
17. Traupe T, Ortmann J, Stoller M, Baumgartner I, de Marchi SF, Seiler C. Direct quantitative 
assessment of the peripheral artery collateral circulation in patients undergoing angiography. 
Circulation. 2013; 128:737–744. [PubMed: 23817577] 
18. Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, Iijima K, Akishita M, Ouchi Y. Induction 
of endothelial nitric oxide synthase, sirt1, and catalase by statins inhibits endothelial senescence 
through the akt pathway. Arterioscler Thromb Vasc Biol. 2010; 30:2205–2211. [PubMed: 
20705918] 
19. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY. Statins activate amp-activated protein 
kinase in vitro and in vivo. Circulation. 2006; 114:2655–2662. [PubMed: 17116771] 
20. Sindler AL, Delp MD, Reyes R, Wu G, Muller-Delp JM. Effects of ageing and exercise training on 
eNOS uncoupling in skeletal muscle resistance arterioles. J Physiol. 2009; 587:3885–3897. 
[PubMed: 19528246] 
21. Werner C, Furster T, Widmann T, Poss J, Roggia C, Hanhoun M, Scharhag J, Buchner N, Meyer 
T, Kindermann W, Haendeler J, Bohm M, Laufs U. Physical exercise prevents cellular senescence 
in circulating leukocytes and in the vessel wall. Circulation. 2009; 120:2438–2447. [PubMed: 
19948976] 
22. Evangelista FS, Brum PC, Krieger JE. Duration-controlled swimming exercise training induces 
cardiac hypertrophy in mice. Braz J Med Biol Res. 2003; 36:1751–1759. [PubMed: 14666261] 
Moore et al. Page 16













23. Caron KM, James LR, Lee G, Kim HS, Smithies O. Lifelong genetic minipumps. Physiol 
Genomics. 2005; 20:203–209. [PubMed: 15585607] 
24. Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Catecholamines augment collateral 
vessel growth and angiogenesis in hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2005; 
289:H947–959. [PubMed: 15833801] 
25. Higuchi M, Yasuda O, Kawamoto H, Yotsui T, Baba Y, Ozaki T, Maeda N, Fukuo K, Rakugi H, 
Ogihara T. Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and 
myocardial microvascular remodeling induced by chronic administration of nomega-nitro-l-
arginine methyl ester in mice. Hypertens Res. 2007; 30:563–571. [PubMed: 17664861] 
26. Arlier Z, Basar M, Kocamaz E, Kiraz K, Tanriover G, Kocer G, Arlier S, Semih G, Nasircilar S, 
Gunduz F, Senturk UK, Demir N. Hypertension alters phosphorylation of vasp in brain endothelial 
cells. Int J Neurosci. 2014:1–29.
27. Levy AS, Chung JC, Kroetsch JT, Rush JW. Nitric oxide and coronary vascular endothelium 
adaptations in hypertension. Vasc Health Risk Manag. 2009; 5:1075–1087. [PubMed: 20057900] 
28. Nguyen A, Thorin-Trescases N, Thorin E. Working under pressure: Coronary arteries and the 
endothelin system. Am J Physiol Regul Integr Comp Physiol. 2010; 298:R1188–1194. [PubMed: 
20237301] 
29. Vita JA, Keaney JF Jr. Endothelial function: A barometer for cardiovascular risk? Circulation. 
2002; 106:640–642. [PubMed: 12163419] 
30. Barton M. Obesity and aging: Determinants of endothelial cell dysfunction and atherosclerosis. 
Pflugers Arch. 2010; 460:825–837. [PubMed: 20635093] 
31. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, Seals DR. Vascular endothelial 
dysfunction with aging: Endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart 
Circ Physiol. 2009; 297:H425–432. [PubMed: 19465546] 
32. Chalothorn D, Faber JE. Formation and maturation of the native cerebral collateral circulation. J 
Mol Cell Cardiol. 2010; 49:251–259. [PubMed: 20346953] 
33. Hazama F, Haebara H, Amano S, Ozaki T. Autoradiographic investigation of cell proliferation in 
the brain of spontaneously hypertensive rats. Acta Neuropathol. 1977; 37:231–6. [PubMed: 
857583] 
34. Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, Stefanadis C. 
Diabetes mellitus-associated vascular impairment: Novel circulating biomarkers and therapeutic 
approaches. J Am Coll Cardiol. 2013; 62:667–676. [PubMed: 23948511] 
35. Forstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. Eur Heart J. 2012; 
33:829–837. [PubMed: 21890489] 
36. Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y. Exercise, vascular wall and 
cardiovascular diseases: An update (part 1). Sports Med. 2008; 38:1009–1024. [PubMed: 
19026018] 
37. Hepple RT. Skeletal muscle: Microcirculatory adaptation to metabolic demand. Med Sci Sports 
Exerc. 2000; 32:117–123. [PubMed: 10647538] 
38. Kashiwagi M, Shinozaki M, Hirakata H, Tamaki K, Hirano T, Tokumoto M, Goto H, Okuda S, 
Fujishima M. Locally activated renin-angiotensin system associated with tgf-beta1 as a major 
factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc 
Nephrol. 2000; 11:616–624. [PubMed: 10752520] 
39. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, 
Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl 
Acad Sci U S A. 1996; 93:13176–13181. [PubMed: 8917564] 
40. Neutel JM. Effect of the renin--angiotensin system on the vessel wall: Using ace inhibition to 
improve endothelial function. J Hum Hypertens. 2004; 18:599–606. [PubMed: 15190263] 
41. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol. 1997; 20:II-26–33.
42. de Marchi SF, Gloekler S, Meier P, Traupe T, Steck H, Cook S, Vogel R, Seiler C. Determinants 
of preformed collateral vessels in the human heart without coronary artery disease. Cardiology. 
2011; 118:198–206. [PubMed: 21701169] 
Moore et al. Page 17













43. Menon BK, Smith EE, Coutts SB, Welsh DG, Faber JE, Goyal M, Hill MD, Demchuk AM, 
Damani Z, Cho KH, Chang HW, Hong JH, Sohn SI. Leptomeningeal collaterals are associated 
with modifiable metabolic risk factors. Ann Neurol. 2013; 74:241–248. [PubMed: 23536377] 
44. Serne EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ, Stehouwer CD. Impaired skin 
capillary recruitment in essential hypertension is caused by both functional and structural capillary 
rarefaction. Hypertension. 2001; 38:238–242. [PubMed: 11509483] 
45. Rizzoni D, De Ciuceis C, Porteri E, Paiardi S, Boari GE, Mortini P, Cornali C, Cenzato M, Rodella 
LF, Borsani E, Rizzardi N, Platto C, Rezzani R, Rosei EA. Altered structure of small cerebral 
arteries in patients with essential hypertension. J Hypertens. 2009; 27:838–845. [PubMed: 
19300112] 
46. Hutchins PM, Darnell AE. Observation of a decreased number of small arterioles in spontaneously 
hypertensive rats. Circ Res. 1974; 34–35:I161–I165.
47. Henrich H, Hertel R, Assmann R. Structural differences in the mesentery microcirculation between 
normotensive and spontaneously hypertensive rats. Pflugers Arch. 1978; 375:153–159. [PubMed: 
567786] 
48. Paiardi S, Rodella LF, De Ciuceis C, Porteri E, Boari GE, Rezzani R, Rizzardi N, Platto C, Tiberio 
GA, Giulini SM, Rizzoni D, Agabiti-Rosei E. Immunohistochemical evaluation of microvascular 
rarefaction in hypertensive humans and in spontaneously hypertensive rats. Clin Hemorheol 
Microcirc. 2009; 42:259–268. [PubMed: 19628891] 
49. Suzuki K, Masawa N, Sakata N, Takatama M. Pathologic evidence of microvascular rarefaction in 
the brain of renal hypertensive rats. J Stroke Cerebrovasc Dis. 2003; 12:8–16. [PubMed: 
17903898] 
50. Coyle P, Heistad DD. Blood flow through cerebral collateral vessels in hypertensive and 
normotensive rats. Hypertension. 1986; 8:II67–71. [PubMed: 3721559] 
51. Hashimoto H, Prewitt RL, Efaw CW. Alterations in the microvasculature of one-kidney, one-clip 
hypertensive rats. Am J Physiol. 1987; 253:H933–940. [PubMed: 3661742] 
52. Stacy DL, Prewitt RL. Attenuated microvascular alterations in coarctation hypertension. Am J 
Physiol. 1989; 256:H213–221. [PubMed: 2912185] 
53. Kobayashi N, DeLano FA, Schmid-Schonbein GW. Oxidative stress promotes endothelial cell 
apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb 
Vasc Biol. 2005; 25:2114–2121. [PubMed: 16037565] 
54. Kubis N, Besnard S, Silvestre JS, Feletou M, Huang PL, Lévy BI, Tedgui A. Decreased arteriolar 
density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the 
constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens. 2002; 20:273–80. 
[PubMed: 11821712] 
55. Faber JE, Chilian WM, Deindl E, van Royen N, Simons M. A brief etymology of the collateral 
circulation. Arterioscler Thromb Vasc Biol. 2014; 34:1854–9. [PubMed: 25012127] 
56. Mees B, Wagner S, Ninci E, Tribulova S, Martin S, van Haperen R, Kostin S, Heil M, de Crom R, 
Schaper W. Endothelial nitric oxide synthase activity is essential for vasodilation during blood 
flow recovery but not for arteriogenesis. Arterioscler Thromb Vasc Biol. 2007; 27:1926–33. 
[PubMed: 17556651] 
57. Fujii T, Onimaru M, Yonemitsu Y, Kuwano H, Sueishi K. Statins restore ischemic limb blood flow 
in diabetic microangiopathy via enos/no upregulation but not via pdgf-bb expression. Am J 
Physiol Heart Circ Physiol. 2008; 294:H2785–2791. [PubMed: 18441206] 
58. Kuwahara N, Sasaki S, Kobara M, Nakata T, Tatsumi T, Irie H, Narumiya H, Hatta T, Takeda K, 
Matsubara H, Hushiki S. Hmg-coa reductase inhibition improves anti-aging klotho protein 
expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J 
Cardiol. 2008; 123:84–90. [PubMed: 17434618] 
59. Pourati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced 
collateralization of severely diseased coronary arteries. Am Heart J. 2003; 146:876–881. [PubMed: 
14597938] 
60. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, Duckwiler GR, Vinuela F, Pineda S, 
Liebeskind DS. Statin enhancement of collateralization in acute stroke. Neurology. 2007; 
68:2129–2131. [PubMed: 17562834] 
Moore et al. Page 18













61. Fernandes T, Magalhaes FC, Roque FR, Phillips MI, Oliveira EM. Exercise training prevents the 
microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: Role of 
micrornas-16, -21, and -126. Hypertension. 2012; 59:513–520. [PubMed: 22215713] 
62. Cacicedo JM, Gauthier MS, Lebrasseur NK, Jasuja R, Ruderman NB, Ido Y. Acute exercise 
activates ampk and enos in the mouse aorta. Am J Physiol Heart Circ Physiol. 2011; 301:H1255–
1265. [PubMed: 21724864] 
63. Yang HT, Ogilvie RW, Terjung RL. Exercise training enhances basic fibroblast growth factor-
induced collateral blood flow. Am J Physiol. 1998; 274:H2053–2061. [PubMed: 9841532] 
64. Lloyd PG, Yang HT, Terjung RL. Arteriogenesis and angiogenesis in rat ischemic hindlimb: Role 
of nitric oxide. Am J Physiol Heart Circ Physiol. 2001; 281:H2528–2538. [PubMed: 11709420] 
65. Yang HT, Ren J, Laughlin MH, Terjung RL. Prior exercise training produces no-dependent 
increases in collateral blood flow after acute arterial occlusion. Am J Physiol Heart Circ Physiol. 
2002; 282:H301–310. [PubMed: 11748075] 
66. Zbinden R, Zbinden S, Billinger M, Windecker S, Meier B, Seiler C. Influence of diabetes mellitus 
on coronary collateral flow: An answer to an old controversy. Heart. 2005; 91:1289–1293. 
[PubMed: 16162618] 
67. Zbinden R, Zbinden S, Meier P, Hutter D, Billinger M, Wahl A, Schmid JP, Windecker S, Meier 
B, Seiler C. Coronary collateral flow in response to endurance exercise training. Eur J Cardiovasc 
Prev Rehabil. 2007; 14:250–257. [PubMed: 17446804] 
68. Schmidt W, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: Physical 
activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular 
disease. Cerebrovasc Dis. 2013; 35:303–312. [PubMed: 23594423] 
69. Emanueli C, Caporali A, Krankel N, Cristofaro B, Van Linthout S, Madeddu P. Type-2 diabetic 
lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an 
impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front Biosci. 
2007; 12:2003–2012. [PubMed: 17127438] 
70. Miller SJ, Norton LE, Murphy MP, Dalsing MC, Unthank JL. The role of the renin-angiotensin 
system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth 
impairment. Am J Physiol Heart Circ Physiol. 2007; 292:H2523–2531. [PubMed: 17277018] 
71. Hattan N, Chilian WM, Park F, Rocic P. Restoration of coronary collateral growth in the zucker 
obese rat: Impact of vegf and ecsod. Basic Res Cardiol. 2007; 102:217–223. [PubMed: 17323199] 
72. Kuliszewski MA, Ward MR, Kowalewski JW, Smith AH, Stewart DJ, Kutryk MJ, Leong-Poi H. A 
direct comparison of endothelial progenitor cell dysfunction in rat metabolic syndrome and 
diabetes. Atherosclerosis. 2013; 226:58–66. [PubMed: 23122188] 
73. Couffinhal T, Silver M, Kearney M, Sullivan A, Witzenbichler B, Magner M, Annex B, Peters K, 
Isner JM. Impaired collateral vessel development associated with reduced expression of vascular 
endothelial growth factor in apoe−/− mice. Circulation. 1999; 99:3188–3198. [PubMed: 
10377084] 
74. Koerselman J, de Jaegere PP, Verhaar MC, van der Graaf Y, Grobbee DE. High blood pressure is 
inversely related with the presence and extent of coronary collaterals. J Hum Hypertens. 2005; 
19:809–817. [PubMed: 16107856] 
75. Liebeskind DS, Starkman S, Jo KD, Ohanian AG, Sayre JW, Yun S, Kim D, Ali LK, Ovbiagele B, 
Towfighi A, Shah SH, Jahan R, Duckwiler G, Vinuela F, Saver J. Blood pressure in acute stroke is 
inversely related to the extent of collaterals. Stroke. 2008; 39:538.
76. Mouquet F, Cuilleret F, Susen S, Sautiere K, Marboeuf P, Ennezat PV, McFadden E, Pigny P, 
Richard F, Hennache B, Vantyghem MC, Bertrand M, Dallongeville J, Jude B, Van Belle E. 
Metabolic syndrome and collateral vessel formation in patients with documented occluded 
coronary arteries: Association with hyperglycaemia, insulin-resistance, adiponectin and 
plasminogen activator inhibitor-1. Eur Heart J. 2009; 30:840–849. [PubMed: 19164335] 
77. Omura-Matsuoka E, Yagita Y, Sasaki T, Terasaki Y, Oyama N, Sugiyama Y, Todo K, Sakoda S, 
Kitagawa K. Hypertension impairs leptomeningeal collateral growth after common carotid artery 
occlusion: Restoration by antihypertensive treatment. J Neurosci Res. 2011; 89:108–116. 
[PubMed: 21046561] 
Moore et al. Page 19













78. You D, Cochain C, Loinard C, Vilar J, Mees B, Duriez M, Levy BI, Silvestre JS. Hypertension 
impairs postnatal vasculogenesis: Role of antihypertensive agents. Hypertension. 2008; 51:1537–
1544. [PubMed: 18426993] 
79. van Weel V, de Vries M, Voshol PJ, Verloop RE, Eilers PH, van Hinsbergh VW, van Bockel JH, 
Quax PH. Hypercholesterolemia reduces collateral artery growth more dominantly than 
hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol. 2006; 26:1383–1390. 
[PubMed: 16574899] 
80. Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolic syndrome. Dis 
Model Mech. 2010; 3:156–166. [PubMed: 20212084] 
81. Yan J, Tie G, Park B, Yan Y, Nowicki PT, Messina LM. Recovery from hind limb ischemia is less 
effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and 
endothelial progenitor cells. J Vasc Surg. 2009; 50:1412–1422. [PubMed: 19837544] 
82. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc 
Res. 2009; 84:24–32. [PubMed: 19586943] 
83. Frasher WG Jr, Wayland H. A repeating modular organization of the microcirculation of cat 
mesentery. Microvasc Res. 1972; 4:62–76. [PubMed: 5036680] 
84. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: Continuous 
labelling studies. Br J Cancer. 1984; 49:405–413. [PubMed: 6201181] 
85. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl 
Acad Sci U S A. 1995; 92:11190–11194. [PubMed: 7479963] 
86. Wang JC, Bennett M. Aging and atherosclerosis: Mechanisms, functional consequences, and 
potential therapeutics for cellular senescence. Circ Res. 2012; 111:245–259. [PubMed: 22773427] 
Moore et al. Page 20













Figure 1. Mean arterial pressure (MAP, via carotid artery, isoflurane anesthesia) and heart rate 
in wildtype littermates (WT) and renin transgenic (RTG) heterozygous (+/−) and homozygous 
(+/+) mice at the indicated ages (mos, months)
Values are mean ± SEM, number of animals (n) indicated in columns, *,**,*** p<0.05, 
0.01, 0.001 levels of significance in this and subsequent figures.
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Figure 2. Hypertension causes greater ischemia and impaired recovery of perfusion after 
femoral artery ligation (FAL)
A, Laser Doppler imaging (LDI) of plantar perfusion (dotted lines identify region of interest 
in representative figure), which correlates with whole limb perfusion, is reduced in 8 
months-old RTG+/− mice immediately after FAL (post-op; inset bar graph), indicating 
reduced native collateral conductance. Lower recovery of perfusion on subsequent days is 
consistent with reduced collateral remodeling (confirmed in Figure 5). B, Perfusion in 
RTG+/− adductor region, which contains the major collateral network recruited by FAL 
(note flow induced after FAL in the two parallel-running collateral pathways in the gracilis 
muscles), is lower immediately after FAL (inset) and trends higher after day-7, consistent 
with the conclusions above for panel A. C, Ischemic nail-beds in RTG+/− mouse one day 
after FAL (arrows in representative figure). Hindlimb use-impairment and ischemic 
appearance scores are greater in RTG+/− mice. D–F, Similar results were obtained in 8 
months-old C57BL/6 mice treated with L-NAME (LN) for 6.5 months and having similar 
hypertension as in RTG+/− mice (20 mmHg increase, Online Table 1). Concomitant 
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administration of hydralazine (Hyd) normalizes the hypertension (Online Table 1), yet the 
perfusion deficit persists, suggesting that nitric oxide synthase inhibition rather than 
hypertension is the primary cause of deficient collateral conductance in L-NAME treated 
mice.
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Figure 3. Chronic hypertension causes collateral rarefaction in skeletal muscle and brain
A, B, mouse groups shown in Figure 2. Eight months-old RTG+/− mice have fewer native 
collaterals (asterisks) of smaller diameter in abdominal wall skeletal muscle and brain 
(decreases shown at top of bars are relative to WT, here and in subsequent figures). C, D, 
Similar effects in L-NAME treated mice (LN) are not prevented by concomitant treatment 
with hydralazine (H). NS, non-significant.
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Figure 4. Collateral rarefaction increases with duration and severity of hypertension
A, B, RTG+/− mice are born with the same number of native collaterals as WT (data not 
shown). By 4 months-age, collateral diameter is reduced; reduction of both number and 
diameter is evident with longer duration of hypertension. RTG+/+ mice with more severe 
hypertension evidence earlier collateral rarefaction. C, Consistent with collateral rarefaction 
shown in Figure 3 in skeletal muscle, plantar perfusion (by LDI) immediately after FAL in 4 
months-old mice is inversely related to the severity of hypertension.
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Figure 5. Larger infarct volume and less outward remodeling of collaterals evident 3 days after 
permanent middle cerebral artery occlusion in 8 months-old RTG+/− hypertensive mice
Remodeling is given as percent increase from baseline for collaterals between MCA and 
ACA trees (shown in representative figure).
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Figure 6. Tortuosity and proliferation in vascular wall cells are greater in native collaterals of 
hypertensive mice
Tortuosity (A) and proliferation of endothelial cells (B, arrows, EdU+ cells) in collaterals 
between MCA and ACA trees are increased during times shown in Figure 4 when 
rarefaction is occurring in RTG hypertensive mice.
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Figure 7. Cardiovascular risk factors in addition to hypertension cause rarefaction of the native 
collateral circulation
A, Eight months-old obese mice (Ob/Ob) have no deficit in hindlimb perfusion immediately 
after FAL (post-op, inset) or recovery of perfusion over subsequent 21 days, but have 
decreased collateral diameter. B, Eight months-old hyperlipidemic mice (LDLR−/−) have 
lower perfusion immediately after FAL and reduced recovery, and trend toward fewer 
collaterals. C, Eight months-old mice with Type 1 diabetes mellitus (DM, Akita) have lower 
perfusion immediately after FAL, impaired recovery, and trend towards fewer collaterals 
(see Online figure 4 and its legend showing significant rarefaction in a different model of 
Type 1 diabetes). D, Eight months-old mice with metabolic syndrome (2KO) have lower 
perfusion immediately after FAL, severe impairment in recovery of perfusion, and greater 
hindlimb use-impairment and ischemic appearance (Online Figure 5), and reduced collateral 
number and diameter.
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